Some of our cancer centers are experiencing issues.  View More Important Notifications x
texas oncology more breakthroughs. more victories

Share:

 
 

Houston Memorial City Research & Clinical Trials

Texas Oncology-Houston Memorial City participates in a wide range of groundbreaking research that is paving the way for new breakthroughs in cancer care. As a Texas Oncology patient, you may be able to take part in these innovative clinical trials.

Texas Oncology-Houston Memorial City (Expand)

Biliary Cancer

STAR Infigratinib vs Gem/Cis Cholangio

A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301) Read More

Phase: III

Bladder Cancer

STAR Sitra+Nivo/Pembro+Enfor Adv/Met Uro

A Phase 2 Study of Sitravatinib in Combination with PD-L (1) Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003) Read More

Phase: II

STAR PH 2 ASG-22CE Urothelial Cancer

A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002) Read More

Phase: I/II

Biomarker Advcd Uro Cncer and FGFR Aber

Biomarker Study to Identify Subjects with Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations (42756493BLC0002) Read More

Phase: IV

Breast Cancer

Ph2 alpelisib+fulves/letrozole HR+ HER2-

BYLieve: A phase II, multicenter, open-label, three-cohort, noncomparative study to assess the efficacy and safety of alpelisib plus fulvestrant or letrozole in patients with PIK3CA mutant,hormone receptor (HR) positive, HER2-negative advanced breast cancer (aBC), who have progressed on or after prior treatments (CBYL719X2402) Read More

Phase: II

FLEX Registry: Evaluate New Gene Express

MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry) Read More

Ph 1b2 LIV1A+Pembro 1L mTNBC

Single Arm, Open Label Phase 1b/2 Study of SGN-LIV1A inCombination with Pembrolizumab for First-Line Treatment ofPatients with Unresectable Locally-Advanced or MetastaticTriple-Negative Breast Cancer (SGNLVA-002) Read More

Phase: I/II

STAR Ph 3 Tuca/Placbo + T-DM1 HER2+

STAR: Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer (HER2CLIMB-02)(SGNTUC-016) Read More

Phase: III

Cervical Cancer

STAR Ph2 Ak104 Cervical Cancer

A Phase 2, multicenter, single-arm, open-label study to evaluate the efficacy and safety of AK104 in subjects with recurrent or metastatic cervical cancer (AK104-201-AU) Read More

Phase: II

Colon Cancer

STAR: PH2 Tuca+ Tras HER2+ CC

MOUNTAINEER: A Phase 2, Open Label Study of Tucatinib Combined with Trastuzumab in Patients with HER2+ Metastatic Colorectal Cancer (ACCRU-GI-1617, SGNTUC-017) Read More

Phase: II

Esophageal Cancer

STAR Ph3 Sinti vs Placebo ESCC

A Multicenter, Double-Blind, Randomized Phase III Clinical Trial Evaluating the Efficacy and Safety of Sintilimab vs. Placebo, in Combination with Chemotherapy, for First-Line Treatment of Unresectable, Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma (ORIENT-15)CIBI308A301 Read More

Phase: III

Essential Thrombocythemia

STAR PH3 Pacritinib vs MD choice in MF

A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician''s Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelets Counts <50,000/µL) (PAC203) Read More

Phase: III

STAR PH3 Pacritinib vs MD choice in MF

A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician''s Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelets Counts <50,000/µL) (PAC203) Read More

Phase: III

Gall Bladder Cancer

STAR Infigratinib vs Gem/Cis Cholangio

A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301) Read More

Phase: III

STAR Infigratinib vs Gem/Cis Cholangio

A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301) Read More

Phase: III

Lung Cancer

STAR Ph1/2 BLU667 thy, NSCLC, Sol tum

A Phase 1/2 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients with Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC), and Other Advanced Solid Tumors Read More

Phase: I/II

STAR Ph1/2 BLU667 thy, NSCLC, Sol tum

A Phase 1/2 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients with Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC), and Other Advanced Solid Tumors Read More

Phase: I/II

STAR-PH3 pral(Blu-667) RET-fusion mNSCLC

A Randomized, Open-Label, Phase 3 Study of Pralsetinib versus Standard of Care for First Line Treatment of RET fusion-positive, Metastatic Non-Small Cell Lung Cancer (BLU-667-2303) Read More

Phase: III

STAR-PH3 pral(Blu-667) RET-fusion mNSCLC

A Randomized, Open-Label, Phase 3 Study of Pralsetinib versus Standard of Care for First Line Treatment of RET fusion-positive, Metastatic Non-Small Cell Lung Cancer (BLU-667-2303) Read More

Phase: III

STAR Ph3 ALK+ mNSCLC (Brigatinib-3001)

Brigatinib-3001- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG®)Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®) Read More

Phase: III

STAR Ph3 ALK+ mNSCLC (Brigatinib-3001)

Brigatinib-3001- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG®)Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®) Read More

Phase: III

Myelofibrosis

STAR PH3 Pacritinib vs MD choice in MF

A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician''s Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelets Counts <50,000/µL) (PAC203) Read More

Phase: III

STAR PH3 Pacritinib vs MD choice in MF

A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician''s Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelets Counts <50,000/µL) (PAC203) Read More

Phase: III

Prostate Cancer

STAR Ph3 Nirap+Abirat+Pred mCRPC

A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Subjects with Metastatic Prostate Cancer(64091742PCR3001) Read More

Phase: III

STAR Ph3 Nirap+Abirat+Pred mCRPC

A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Subjects with Metastatic Prostate Cancer(64091742PCR3001) Read More

Phase: III

STAR Abirat+pred +/- abemaciclib mCRPC

CYCLONE 2: A Phase 2, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer (I3Y-MC-JPCM) Read More

Phase: II

STAR Abirat+pred +/- abemaciclib mCRPC

CYCLONE 2: A Phase 2, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer (I3Y-MC-JPCM) Read More

Phase: II

STAR Rucaparib v PhysC mCRPC (TRITON3)

TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063) Read More

Phase: III

STAR Rucaparib v PhysC mCRPC (TRITON3)

TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063) Read More

Phase: III

Rectal Cancer

STAR: PH2 Tuca+ Tras HER2+ CC

MOUNTAINEER: A Phase 2, Open Label Study of Tucatinib Combined with Trastuzumab in Patients with HER2+ Metastatic Colorectal Cancer (ACCRU-GI-1617, SGNTUC-017) Read More

Phase: II

STAR: PH2 Tuca+ Tras HER2+ CC

MOUNTAINEER: A Phase 2, Open Label Study of Tucatinib Combined with Trastuzumab in Patients with HER2+ Metastatic Colorectal Cancer (ACCRU-GI-1617, SGNTUC-017) Read More

Phase: II

Renal Cancer

PH3 Ate +Cabo Renal Carcinoma

A PHASE III, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB GIVEN IN COMBINATION WITH CABOZANTINIB VERSUS CABOZANTINIB ALONE IN PATIENTS WITH INOPERABLE, LOCALLY ADVANCED, OR METASTATIC RENAL CELL CARCINOMA WHO EXPERIENCED RADIOGRAPHIC TUMOR PROGRESSION DURING OR AFTER IMMUNE CHECKPOINT INHIBITOR TREATMENT (WO41994) Read More

Phase: III

PH3 Ate +Cabo Renal Carcinoma

A PHASE III, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB GIVEN IN COMBINATION WITH CABOZANTINIB VERSUS CABOZANTINIB ALONE IN PATIENTS WITH INOPERABLE, LOCALLY ADVANCED, OR METASTATIC RENAL CELL CARCINOMA WHO EXPERIENCED RADIOGRAPHIC TUMOR PROGRESSION DURING OR AFTER IMMUNE CHECKPOINT INHIBITOR TREATMENT (WO41994) Read More

Phase: III

Skin Cancer

STAR Ph1 CX-4945 Basal Cell Carcinoma

A Phase I, Multi-Center, Open-Label, Treatment Duration Increment, Expansion, Safety, and Pharmacodynamic Study of CX-4945 Administered Orally Twice Daily to Patients with Advanced Basal Cell Carcinoma (CX-4945-07) Read More

Phase: I

STAR Ph1 CX-4945 Basal Cell Carcinoma

A Phase I, Multi-Center, Open-Label, Treatment Duration Increment, Expansion, Safety, and Pharmacodynamic Study of CX-4945 Administered Orally Twice Daily to Patients with Advanced Basal Cell Carcinoma (CX-4945-07) Read More

Phase: I

Solid Tumors

STAR Ph2 Pemigatinib Solids FGFR

(INCB 54828-207) A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) Read More

Phase: II

STAR Ph2 Pemigatinib Solids FGFR

(INCB 54828-207) A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) Read More

Phase: II

STAR Ph1/2 BLU667 thy, NSCLC, Sol tum

A Phase 1/2 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients with Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC), and Other Advanced Solid Tumors Read More

Phase: I/II

STAR Ph1/2 BLU667 thy, NSCLC, Sol tum

A Phase 1/2 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients with Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC), and Other Advanced Solid Tumors Read More

Phase: I/II

Thyroid Cancer

STAR Ph1/2 BLU667 thy, NSCLC, Sol tum

A Phase 1/2 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients with Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC), and Other Advanced Solid Tumors Read More

Phase: I/II

STAR Ph1/2 BLU667 thy, NSCLC, Sol tum

A Phase 1/2 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients with Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC), and Other Advanced Solid Tumors Read More

Phase: I/II

Urothelial Cancer

STAR Ph3 FGFR erdafitinib urothelial

(42756493BLC3001) A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations (THOR) Read More

Phase: III

STAR Ph3 FGFR erdafitinib urothelial

(42756493BLC3001) A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations (THOR) Read More

Phase: III

STAR Sitra+Nivo/Pembro+Enfor Adv/Met Uro

A Phase 2 Study of Sitravatinib in Combination with PD-L (1) Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003) Read More

Phase: II

STAR Sitra+Nivo/Pembro+Enfor Adv/Met Uro

A Phase 2 Study of Sitravatinib in Combination with PD-L (1) Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003) Read More

Phase: II

STAR PH 2 ASG-22CE Urothelial Cancer

A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002) Read More

Phase: I/II

STAR PH 2 ASG-22CE Urothelial Cancer

A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002) Read More

Phase: I/II

Biomarker Advcd Uro Cncer and FGFR Aber

Biomarker Study to Identify Subjects with Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations (42756493BLC0002) Read More

Phase: IV

Biomarker Advcd Uro Cncer and FGFR Aber

Biomarker Study to Identify Subjects with Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations (42756493BLC0002) Read More

Phase: IV

STAR Ph 3 Infigratinib UC w/ FGFR3 Alt

QBGJ398-302: Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects with Invasive Urothelial Carcinoma with Susceptible FGFR3 Genetic Alterations (PROOF302) Read More

Phase: III

STAR Ph 3 Infigratinib UC w/ FGFR3 Alt

QBGJ398-302: Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects with Invasive Urothelial Carcinoma with Susceptible FGFR3 Genetic Alterations (PROOF302) Read More

Phase: III